While institutions own 40 percent of Aurinia Pharmaceuticals Inc. , retail investors are its largest shareholders with 52 percent ownership
AUPH Stock | USD 9.12 0.14 1.56% |
Under 69 percent of all Aurinia Pharmaceuticals' traders are curious in acquiring. The analysis of the overall investor sentiment regarding Aurinia Pharmaceuticals suggests that a large number of traders are confidant. Aurinia Pharmaceuticals' investing sentiment shows overall attitude of investors towards Aurinia Pharmaceuticals.
Aurinia |
Key Insights The considerable ownership by retail investors in Aurinia Pharmaceuticals indicates that they collectively...
Read at finance.yahoo.com
Aurinia Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Aurinia Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Aurinia Pharmaceuticals Fundamental Analysis
We analyze Aurinia Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aurinia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aurinia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Aurinia Pharmaceuticals is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Aurinia Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aurinia Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aurinia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aurinia Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aurinia Pharmaceuticals Related Equities
BTAI | BioXcel Therapeutics | 4.77 | ||||
PTCT | PTC Therapeutics | 1.41 | ||||
EXEL | Exelixis | 1.02 | ||||
AKRO | Akero Therapeutics | 0.63 | ||||
AXSM | Axsome Therapeutics | 0.21 | ||||
VKTX | Viking Therapeutics | 0.07 | ||||
SRPT | Sarepta Therapeutics | 0.00 | ||||
MDGL | Madrigal Pharmaceuticals | 0.03 | ||||
HEPA | Hepion Pharmaceuticals | 0.20 | ||||
TGTX | TG Therapeutics | 0.31 | ||||
TERN | Terns Pharmaceuticals | 2.19 | ||||
MCRB | Seres Therapeutics | 3.64 |
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |